Sunitinib
| Evidence Level: L2 | Predicted Indications: 5 |
Table of Contents
Sunitinib: From Renal Cell Carcinoma to Liposarcoma
One-Sentence Summary
Sunitinib is an oral multi-targeted kinase inhibitor, originally used to treat renal cell carcinoma and gastrointestinal stromal tumour (GIST). The TxGNN model predicts it may be effective for liposarcoma, with 2 completed Phase 2 clinical trials and 8 publications (including one Phase 2 study and one case report) currently supporting this direction. The evidence is modest and histology-dependent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Renal cell carcinoma (nonpapillary, clear cell) and gastrointestinal stromal tumour |
| Predicted New Indication | Liposarcoma |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 18 of 18) |
| Number of DINs | 18 (marketed: 18) |
| Recommended Decision | Hold (treat as a research question; see Conclusion) |
Why is This Prediction Reasonable?
Sunitinib blocks several receptor tyrosine kinases, including VEGFR, PDGFR, KIT, FLT3 and RET. These drive tumour angiogenesis and cell proliferation. Detailed mechanism of action data is not otherwise available in the data compiled for this report, so this description comes from the repurposing analysis.
Renal cell carcinoma and GIST are both tumours in which these pathways play a major role. Soft tissue sarcomas, including liposarcoma, also depend on angiogenesis and growth-factor signalling, which gives a plausible reason why a drug that works in these cancers could have some activity in liposarcoma.
The clinical signal is modest. A published Phase 2 study in relapsed or refractory soft tissue sarcoma, focused on leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma, suggests limited activity. Response appears to depend on the sarcoma subtype. The current evidence supports further hypothesis-driven study rather than adoption in practice.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00474994 | Phase 2 | Completed | 53 | Continuous-dose sunitinib in metastatic, locally advanced or recurrent non-GIST sarcomas; liposarcoma is a directly relevant subtype |
| NCT00400569 | Phase 2 | Completed | 48 | Open-label single-site study of sunitinib in metastatic or unresectable soft tissue sarcoma, including liposarcoma; mixed population, so liposarcoma-specific data are uncertain |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21154746 | 2011 | Phase 2 trial | Int J Cancer | Sunitinib in relapsed or refractory soft tissue sarcoma, focused on leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma |
| 24555529 | 2014 | Review | Expert Rev Anticancer Ther | Emerging therapies for adult soft tissue sarcoma, with subtype-specific second-line options |
| 24712007 | 2014 | Review | Magy Onkol | Soft tissue sarcoma treatment guided by histological subtype |
| 22987955 | 2012 | Review | Ann Oncol | Histology-driven therapy for soft tissue sarcomas; trabectedin has notable activity in liposarcoma |
| 23482782 | 2013 | Case report | Anticancer Res | Long-lasting clinical benefit of sunitinib in a heavily pre-treated metastatic liposarcoma |
| 38254762 | 2024 | Molecular profiling study | Cancers | Genetic, epigenetic and transcriptome alterations in liposarcoma for target therapy selection |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02280809 | SUTENT | – | – |
| 02280795 | SUTENT | – | – |
| 02280817 | SUTENT | – | – |
| 02532867 | SANDOZ SUNITINIB | – | – |
| 02524066 | TARO-SUNITINIB | – | – |
Eighteen DINs are valid in total. All are single-ingredient products, including SUTENT and generics from Auro, Sandoz, Taro, NAT and Teva. Dosage form and approved indication text were not available in the data compiled for this report.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (multi-targeted tyrosine kinase inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Medium (thrombocytopenia and anaemia appear among the related conditions of concern) |
| Emetogenicity Classification | Low to medium |
| Monitoring Items | CBC with platelets, liver function, thyroid function, electrolytes, blood pressure, cardiac function and ECG (QT interval) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Conditions flagged as contraindications or cautions (knowledge graph data, not label text):
- Cardiac: long QT syndrome, torsades de pointes, heart failure
- Liver: liver failure, liver disease, drug-induced liver injury, hyperbilirubinaemia (including Gilbert syndrome)
- Endocrine: hypothyroidism, hyperthyroidism, adrenal insufficiency
- Blood: thrombocytopenia, anaemia
- Other: epilepsy, pancreatitis, gallbladder disease, potassium deficiency, posterior leukoencephalopathy syndrome
- Drug Interactions: 100 interactions were identified. Of the 20 listed, one is Major: dolasetron. The others are Moderate, for example:
- Clarithromycin
- Dexamethasone
- Famotidine
- Loperamide
- Palonosetron
- Bowel-preparation laxatives
- Insulins and sulfonylureas (chlorpropamide, glimepiride)
- Sunitinib-induced thrombotic microangiopathy has been reported in the literature and requires monitoring.
Official package insert warnings and contraindications were not available, so please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Two completed Phase 2 trials and one published Phase 2 study point to modest, histology-dependent activity in liposarcoma. The trials enrolled mixed sarcoma populations, so liposarcoma-specific efficacy is unproven.
- Established sarcoma options (for example trabectedin in liposarcoma) are discussed in the literature, so sunitinib is best treated as a research question.
To proceed, the following is needed:
- Liposarcoma-specific subgroup results from NCT00474994, NCT00400569 and PMID 21154746
- Comparison against current standard second-line options in liposarcoma
- Official package insert warnings and contraindications from Health Canada
- Detailed mechanism of action data
- A safety monitoring plan covering cardiac (QT), liver and thyroid risks, and review of the major dolasetron interaction
Other predicted indications (brief note):
- Unclassified renal cell carcinoma (L2): several Phase 2 studies including ASPEN, with sunitinib often as the comparator. This lies within the original renal cell carcinoma indication family.
- Dermatofibrosarcoma protuberans (L3): a mechanistically sound option after imatinib failure, supported by a retrospective series and case reports.
- Renal carcinoma (L1): strong Phase 3 evidence, but it overlaps the already-approved indication and is not a true repurposing finding.
- Hold: ovarian myxoid liposarcoma, renal cell carcinoma associated with neuroblastoma, angiolipoma and heart fibrosarcoma, which have little or no disease-specific evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.